Study Background

The RUNX1 transcription factor plays a central role in hematopoiesis. Individuals harboring mutations have increased risk of bleeding, bruising, and hematologic malignancies. This study evaluates the effect of imatinib on platelet function and inflammatory biomarkers in non‑malignant carriers.

Clinical Design

This is a Phase 1 trial currently recruiting. Eligible participants are adults (≥ 18 years) with a confirmed RUNX1 mutation. Imatinib will be administered orally once daily, with cohorts stratified by 28‑day or 84‑day treatment durations. Blood draws and questionnaires will be performed bi‑weekly, with bone‑marrow aspirates added as needed. The primary endpoints focus on dose optimization and changes in platelet and inflammatory markers, with safety also assessed.

Current Treatment Landscape and Differentiation

There is no approved standard therapy for RUNX1 deficiency; management is limited to symptom control and routine monitoring. Imatinib, a BCR‑ABL inhibitor that also blocks KIT and PDGFR signaling, has been proposed to improve platelet function. Unlike conventional supportive care, this approach modulates transcription‑factor activity at the molecular level, representing a distinct therapeutic strategy.

Potential Impact of Success or Failure

If the trial demonstrates positive outcomes, preventive targeted therapy could become feasible for asymptomatic carriers, potentially expanding clinical guidelines. This would provide compelling evidence for biopharma companies to develop pipelines focused on hematologic cancer prevention and represent a differentiated early‑stage investment opportunity. Conversely, a negative result could heighten skepticism toward transcription‑factor–based preventive strategies.